BRPI0916862A2 - compostos úteis para o tratamento de doenças degenerativas e inflamatórias - Google Patents

compostos úteis para o tratamento de doenças degenerativas e inflamatórias

Info

Publication number: BRPI0916862A2
Authority: BR; Brazil
Prior art keywords: degenerative; treatment; inflammatory diseases; compounds useful; compounds
Prior art date: 2008-07-25

Application number

BRPI0916862A

Other languages

English (en)

Inventor

Christel Jeanne Marie Menet

Javier Blanc

Original Assignee

Galapagos Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-07-25

Filing date

2009-07-24

Publication date

2016-02-10

2009-07-24 Application filed by Galapagos Nv filed Critical Galapagos Nv

2016-02-10 Publication of BRPI0916862A2 publication Critical patent/BRPI0916862A2/pt

2020-08-11 Publication of BRPI0916862B1 publication Critical patent/BRPI0916862B1/pt

2021-05-25 Publication of BRPI0916862B8 publication Critical patent/BRPI0916862B8/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Toxicology (AREA)
Biomedical Technology (AREA)
Surgery (AREA)
Hospice & Palliative Care (AREA)
Dermatology (AREA)
Otolaryngology (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

BRPI0916862A 2008-07-25 2009-07-24 compostos úteis para o tratamento de doenças degenerativas e inflamatórias, seu uso, bem como composição farmacêutica BRPI0916862B8 (pt)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US13592008P	2008-07-25	2008-07-25
US61/135,920		2008-07-25
US22068509P	2009-06-26	2009-06-26
US61/220,685		2009-06-26
PCT/EP2009/059605 WO2010010191A1 (en)	2008-07-25	2009-07-24	Novel compounds useful for the treatment of degenerative and inflammatory diseases.

Publications (3)

Publication Number	Publication Date
BRPI0916862A2 true BRPI0916862A2 (pt)	2016-02-10
BRPI0916862B1 BRPI0916862B1 (pt)	2020-08-11
BRPI0916862B8 BRPI0916862B8 (pt)	2021-05-25

Family

ID=41021059

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
BRPI0916659A BRPI0916659B8 (pt)	2008-07-25	2009-07-24	compostos úteis para o tratamento de doenças degenerativas e inflamatórias e seus usos
BRPI0916862A BRPI0916862B8 (pt)	2008-07-25	2009-07-24	compostos úteis para o tratamento de doenças degenerativas e inflamatórias, seu uso, bem como composição farmacêutica

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
BRPI0916659A BRPI0916659B8 (pt)	2008-07-25	2009-07-24	compostos úteis para o tratamento de doenças degenerativas e inflamatórias e seus usos

Country Status (35)

Country	Link
US (5)	US8853240B2 (pt)
EP (2)	EP2361251B1 (pt)
JP (2)	JP5480261B2 (pt)
KR (2)	KR101711911B1 (pt)
CN (2)	CN102105471B (pt)
AR (1)	AR072875A1 (pt)
AU (2)	AU2009273144B2 (pt)
BR (2)	BRPI0916659B8 (pt)
CA (2)	CA2730762C (pt)
CL (1)	CL2009001637A1 (pt)
CO (1)	CO6361925A2 (pt)
CR (1)	CR20110092A (pt)
CY (2)	CY1113945T1 (pt)
DK (2)	DK2361251T3 (pt)
DO (1)	DOP2011000022A (pt)
EA (2)	EA018587B1 (pt)
ES (2)	ES2406691T3 (pt)
HR (2)	HRP20140681T1 (pt)
IL (2)	IL210262A (pt)
JO (1)	JO3041B1 (pt)
MA (1)	MA32551B1 (pt)
ME (1)	ME02046B (pt)
MX (2)	MX2011000758A (pt)
MY (1)	MY157615A (pt)
NZ (1)	NZ590646A (pt)
PE (1)	PE20100152A1 (pt)
PL (2)	PL2361251T3 (pt)
PT (2)	PT2361251E (pt)
RS (2)	RS52823B (pt)
SI (2)	SI2361251T1 (pt)
SM (2)	SMT201300051B (pt)
TW (1)	TWI447118B (pt)
UY (1)	UY32006A (pt)
WO (2)	WO2010010190A1 (pt)
ZA (2)	ZA201100396B (pt)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0719803D0 (en)	2007-10-10	2007-11-21	Cancer Rec Tech Ltd	Therapeutic compounds and their use
JO3041B1 (ar)	2008-07-25	2016-09-05	Galapagos Nv	مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010141796A2 (en)	2009-06-05	2010-12-09	Cephalon, Inc.	PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES
TWI462920B (zh)	2009-06-26	2014-12-01	葛萊伯格有限公司	用於治療退化性及發炎疾病之新穎化合物
US20100331222A1 (en) *	2009-06-26	2010-12-30	Basf Se	Process for producing cellulose beads from solutions of cellulose in ionic liquid
JO3030B1 (ar) *	2009-06-26	2016-09-05	Galapagos Nv	مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
WO2011140333A1 (en)	2010-05-07	2011-11-10	The Board Of Trustees Of The Leland Stanford Junior University	Identification of stabilizers of multimeric proteins
EP2588105A1 (en)	2010-07-01	2013-05-08	Cellzome Limited	Triazolopyridines as tyk2 inhibitors
AR086042A1 (es) *	2011-04-28	2013-11-13	Galapagos Nv	Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica
SG10201805807PA (en)	2012-06-26	2018-08-30	Del Mar Pharmaceuticals	Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
US9169214B2 (en)	2012-12-21	2015-10-27	The Board Of Trustees Of The Leland Stanford Junior University	Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
CN103965114B (zh) *	2013-01-28	2016-01-06	苏州泽璟生物制药有限公司	氘代的苯基氨基嘧啶化合物以及包含该化合物的药物组合物
WO2014118388A1 (en)	2013-02-04	2014-08-07	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for assaying jak2 activity in red blood cells and uses thereof
JP6435323B2 (ja) *	2013-06-19	2018-12-05	ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓＮ．Ｖ．	炎症性障害の治療のための新規化合物及びその医薬組成物
ES2654051T3 (es)	2013-12-05	2018-02-12	Pfizer Inc.	Pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinil acrilamidas
CA2934251C (en)	2013-12-20	2024-01-02	3-V Biosciences, Inc.	A combination of heterocyclic modulators of lipid synthesis and chemotherapeutic drugs in treatment of cancer
GB201402070D0 (en)	2014-02-07	2014-03-26	Galapagos Nv	Pharmaceutical compositions for the treatment of inflammatory disorders
GB201402071D0 (en) *	2014-02-07	2014-03-26	Galapagos Nv	Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US20160045609A1 (en)	2014-08-14	2016-02-18	Mamoun M. Alhamadsheh	Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
TWI679205B (zh)	2014-09-02	2019-12-11	日商日本新藥股份有限公司	吡唑并噻唑化合物及醫藥
EP3250572B1 (en)	2015-01-28	2020-08-26	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.	Substituted imidazo [1, 2-a]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof
SG11201708181RA (en) *	2015-04-13	2017-11-29	Galapagos Nv	Methods for the treatment of inflammatory disorders
EP3290418B1 (en) *	2015-04-29	2019-05-15	Wuxi Fortune Pharmaceutical Co., Ltd	Janus kinase (jak) inhibitors
WO2016179207A1 (en) *	2015-05-05	2016-11-10	Concert Pharmaceuticals, Inc.	Deuterated filgotinib
CN105061420B (zh) *	2015-06-04	2017-09-05	南京旗昌医药科技有限公司	一种jak抑制剂的晶型及其制备方法和应用
CN104987333B (zh) *	2015-07-14	2017-01-11	苏州富士莱医药股份有限公司	一种Filgotinib的合成方法
WO2017012771A1 (en)	2015-07-23	2017-01-26	Ratiopharm Gmbh	Crystalline filgotinib sulfonic acid addition salts
WO2017012773A1 (en)	2015-07-23	2017-01-26	Ratiopharm Gmbh	Solid forms of filgotinib free base
WO2017012770A1 (en)	2015-07-23	2017-01-26	Ratiopharm Gmbh	Acid addition salts of filgotinib
CN105198879B (zh) *	2015-09-18	2017-09-22	上海宣创生物科技有限公司	一种环丙烷甲酰胺衍生物c晶型及其制备方法
CN105198876B (zh) *	2015-09-18	2017-09-29	上海宣创生物科技有限公司	一种环丙烷甲酰胺衍生物h晶型及其制备方法
CN105111206B (zh) *	2015-09-18	2017-07-25	上海宣创生物科技有限公司	一种环丙烷甲酰胺衍生物e晶型及其制备方法
CN105218539B (zh) *	2015-09-18	2017-07-25	上海宣创生物科技有限公司	一种环丙烷甲酰胺衍生物b晶型及其制备方法
CN105198880B (zh) *	2015-09-18	2017-07-25	上海宣创生物科技有限公司	一种环丙烷甲酰胺衍生物a晶型及其制备方法
CN105111207B (zh) *	2015-09-18	2017-07-25	上海宣创生物科技有限公司	一种环丙烷甲酰胺衍生物d晶型及其制备方法
CN105198878B (zh) *	2015-09-18	2017-07-25	上海宣创生物科技有限公司	一种环丙烷甲酰胺衍生物f晶型及其制备方法
CN105198877B (zh) *	2015-09-18	2017-09-22	上海宣创生物科技有限公司	一种环丙烷甲酰胺衍生物g晶型及其制备方法
CN108349974B (zh) *	2016-02-02	2021-04-30	深圳市塔吉瑞生物医药有限公司	一种取代的吡啶酰胺类化合物及其应用
TWI712604B (zh)	2016-03-01	2020-12-11	日商日本新藥股份有限公司	具jak抑制作用之化合物之結晶
JP6978097B2 (ja) *	2016-07-26	2021-12-08	スーヂョウロングバイオテックファーマシューティカルズカンパニーリミテッドSuzhou Longbiotech Pharmaceuticals Co., Ltd.	Ｊａｋ阻害剤としての複素環化合物、該化合物の塩類および治療への使用
JOP20190024A1 (ar)	2016-08-26	2019-02-19	Gilead Sciences Inc	مركبات بيروليزين بها استبدال واستخداماتها
CN107880038B (zh) *	2016-09-30	2021-09-28	中国医药研究开发中心有限公司	[1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
JOP20190077A1 (ar) *	2016-10-10	2019-04-09	Array Biopharma Inc	مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
CA3039676A1 (en) *	2016-10-26	2018-05-03	Janssen Pharmaceutica Nv	Fused bicylic pyridine compounds and their use as ampa receptor modulators
CN109890823B (zh) *	2016-10-26	2021-11-30	詹森药业有限公司	稠合氮杂环化合物及其作为ampa受体调节剂的用途
EA039344B1 (ru) *	2017-01-19	2022-01-17	Сучжоу Лонгбайотек Фармасьютикалз Ко., Лтд.	Гетероциклическое соединение в качестве ингибитора jak и его соли и терапевтическое применение
CN108341814B (zh) *	2017-01-23	2021-09-03	上海翔锦生物科技有限公司	Jak激酶抑制剂及其应用
CN116730921A (zh)	2017-02-17	2023-09-12	文涵治疗有限公司	Ag-10的制备方法、其中间体及其盐
GB201702603D0 (en)	2017-02-17	2017-04-05	Galápagos Nv	Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
JOP20180018A1 (ar)	2017-03-14	2019-01-30	Gilead Sciences Inc	تركيبات صيدلية تتضمن مثبط jak
WO2018167283A1 (en)	2017-03-17	2018-09-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
WO2018189335A1 (en)	2017-04-13	2018-10-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
CN111479810B (zh) *	2018-01-31	2022-11-22	珠海联邦制药股份有限公司	Jak抑制剂及其应用
US10836769B2 (en)	2018-02-26	2020-11-17	Gilead Sciences, Inc.	Substituted pyrrolizine compounds and uses thereof
CA3090545A1 (en)	2018-02-28	2019-09-06	University Of Southern California	Compositions and methods for modulating inflammatory and degenerative disorder
SG11202009073WA (en)	2018-03-23	2020-10-29	Eidos Therapeutics Inc	Methods of treating ttr amyloidosis using ag10
GB201808575D0 (en)	2018-05-24	2018-07-11	Galapagos Nv	Methods for the treatment of psoriatic arthrits
EP3836920B1 (en)	2018-08-17	2025-10-01	Eidos Therapeutics, Inc.	Formulations of ag10
ES2973331T3 (es) *	2018-08-23	2024-06-19	Zhuhai United Laboratories Co Ltd	Compuesto de [1,2,4]triazolo[1,5-a]piridina como inhibidor de JAK y aplicación del mismo
US10815227B2 (en)	2018-08-27	2020-10-27	Cadila Healthcare Limited	Processes for the preparation of filgotinib
WO2020092015A1 (en)	2018-11-02	2020-05-07	University Of Rochester	Therapeutic mitigation of epithelial infection
WO2020097396A1 (en)	2018-11-07	2020-05-14	Dana-Farber Cancer Institute, Inc.	Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
WO2020097400A1 (en) *	2018-11-07	2020-05-14	Dana-Farber Cancer Institute, Inc.	Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof
WO2020097398A1 (en)	2018-11-07	2020-05-14	Dana-Farber Cancer Institute, Inc.	Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
US11633399B2 (en)	2018-12-25	2023-04-25	Sol-Gel Technologies Ltd.	Treatment of skin disorders with compositions comprising an EGFR inhibitor
US11427558B1 (en)	2019-07-11	2022-08-30	ESCAPE Bio, Inc.	Indazoles and azaindazoles as LRRK2 inhibitors
WO2021023207A1 (zh) *	2019-08-06	2021-02-11	江苏柯菲平医药股份有限公司	Jak激酶抑制剂及其用途
US12214216B1 (en)	2019-10-16	2025-02-04	Helen Feng	Photon enhanced bone growth system and method
CN111072655B (zh) *	2019-12-30	2021-12-10	深圳市坤健创新药物研究院	一种三氮唑并吡啶类化合物及其制备方法和药用组合物与应用
CN115066425B (zh) *	2020-02-13	2023-06-23	珠海联邦制药股份有限公司	Jak抑制剂在制备治疗jak激酶相关疾病药物中的应用
ES3037893T3 (en) *	2020-02-21	2025-10-07	Zhuhai United Laboratories Co Ltd	Crystalline form of jak inhibitor and application thereof
WO2021226261A1 (en)	2020-05-06	2021-11-11	Ajax Therapeutics, Inc.	6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
CN111617318B (zh) *	2020-05-26	2021-12-10	南京市儿童医院	可注射型儿童骺板再生水凝胶的制备方法
CN114075189A (zh) *	2020-08-11	2022-02-22	南京柯菲平盛辉制药有限公司	五元杂环并苯环类化合物及其制备方法和医药用途
CN114075188A (zh) *	2020-08-11	2022-02-22	南京柯菲平盛辉制药有限公司	芳香杂环酰胺类化合物及其制备方法和医药用途
US12043632B2 (en)	2020-12-23	2024-07-23	Ajax Therapeutics, Inc.	6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
CN114394965B (zh) *	2021-01-29	2023-09-12	深圳市乐土生物医药有限公司	三唑并吡啶类化合物及其制备方法与用途
WO2023086320A1 (en)	2021-11-09	2023-05-19	Ajax Therapeutics, Inc.	Forms and compositions of inhibitors of jak2
CA3234638A1 (en)	2021-11-09	2023-05-19	Ajax Therapeutics, Inc.	6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
CN113773322B (zh) *	2021-11-10	2022-02-11	奥锐特药业(天津)有限公司	一种Filgotinib的制备方法
CN116354955A (zh) *	2021-12-28	2023-06-30	上海科胜药物研发有限公司	一种菲戈替尼的制备方法
CN116496268A (zh) *	2022-01-18	2023-07-28	盛世泰科生物医药技术(苏州)有限公司	一种含环丙酰胺化合物及其应用
US11596612B1 (en)	2022-03-08	2023-03-07	PTC Innovations, LLC	Topical anesthetics
US11746108B1 (en) *	2022-06-13	2023-09-05	Apm Therapeutics 1, Inc.	Triazolopyridine polymorph A
CN116687925B (zh) *	2022-11-04	2024-10-22	中国科学院遗传与发育生物学研究所	一种侵蚀性蛋白酶抑制剂及其应用
LU505465B1 (en) *	2022-11-16	2024-05-14	Adlai Nortye Biopharma Co Ltd	A pan-KRAS inhibitor compound
CN119462650B (zh) *	2024-11-20	2025-10-17	沈阳药科大学	一种非戈替尼的合成方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2228451T3 (es)	1999-01-29	2005-04-16	Chugai Seiyaku Kabushiki Kaisha	Promotores de condrogenesis y derivados de indolin-2-ona.
US20040138285A1 (en)	2001-04-27	2004-07-15	Makoto Okazaki	Chondrogenesis promoters
US6514989B1 (en) *	2001-07-20	2003-02-04	Hoffmann-La Roche Inc.	Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
EP1601672B1 (en)	2003-02-14	2006-07-26	Pfizer Products Inc.	Triazolo-pyridines as anti-inflammatory compounds
TWI221602B (en) *	2003-07-21	2004-10-01	Benq Corp	Emergent disc-withdrawing apparatus
US20050222171A1 (en) *	2004-01-22	2005-10-06	Guido Bold	Organic compounds
WO2005124342A2 (en)	2004-06-21	2005-12-29	Galapagos N.V.	Methods and means for treatment of osteoarthritis
JP2008509987A (ja)	2004-08-18	2008-04-03	ファルマシアアンドアップジョンカンパニーリミテッドライアビリティカンパニー	トリアゾロピリジン化合物
JP2008515874A (ja)	2004-10-07	2008-05-15	ワーナー−ランバートカンパニーリミテッドライアビリティーカンパニー	抗菌薬
GB0515026D0 (en) *	2005-07-21	2005-08-31	Novartis Ag	Organic compounds
JP5336375B2 (ja) *	2006-08-30	2013-11-06	セルゾームリミテッド	キナーゼ阻害剤としてのトリアゾール誘導体
WO2008065198A1 (en) *	2006-12-01	2008-06-05	Galapagos N.V.	Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases
CL2008001626A1 (es) *	2007-06-05	2009-06-05	Takeda Pharmaceuticals Co	Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
AR067562A1 (es) *	2007-07-18	2009-10-14	Novartis Ag	Compuestos heterociclicos inhibidores de kinasa
WO2009017954A1 (en)	2007-08-01	2009-02-05	Phenomix Corporation	Inhibitors of jak2 kinase
KR20100075881A (ko) *	2007-08-31	2010-07-05	메르크 세로노 에스. 에이.	트리아졸로피리딘 화합물 및 ａｓｋ 저해제로서 이의 용도
GB0719803D0 (en) *	2007-10-10	2007-11-21	Cancer Rec Tech Ltd	Therapeutic compounds and their use
US9088430B2 (en) *	2008-02-19	2015-07-21	Qualcomm Incorporated	Providing network originated push messages for remotely testing a mobile device
US20090217316A1 (en) *	2008-02-22	2009-08-27	Binita Gupta	Systems and Methods for Advertising Insertion Notification in a Real-Time Streaming Media Service
US20100035875A1 (en)	2008-06-20	2010-02-11	Bing-Yan Zhu	Triazolopyridine jak inhibitor compounds and methods
WO2010010184A1 (en)	2008-07-25	2010-01-28	Galapagos Nv	[1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010010188A1 (en)	2008-07-25	2010-01-28	Galapagos Nv	Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010187A1 (en)	2008-07-25	2010-01-28	Galapagos Nv	Novel compounds useful for the treatment of degenerative and inflammatory diseases
JO3041B1 (ar) *	2008-07-25	2016-09-05	Galapagos Nv	مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010010186A1 (en) *	2008-07-25	2010-01-28	Galapagos Nv	Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010189A1 (en)	2008-07-25	2010-01-28	Galapagos Nv	Novel compounds useful for the treatment of degenerative and inflammatory diseases
DE102009000543A1 (de) *	2009-02-02	2010-08-12	Evonik Degussa Gmbh	Verfahren, Absorptionsmedien und Vorrichtung zur Absorption von CO2 aus Gasmischungen
PL2391435T3 (pl) *	2009-02-02	2014-05-30	Basf Se	Absorbent zawierający cykliczne aminy do usuwania kwaśnych gazów
WO2010141796A2 (en)	2009-06-05	2010-12-09	Cephalon, Inc.	PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES
JO3030B1 (ar)	2009-06-26	2016-09-05	Galapagos Nv	مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
TWI462920B (zh)	2009-06-26	2014-12-01	葛萊伯格有限公司	用於治療退化性及發炎疾病之新穎化合物
WO2013173506A2 (en)	2012-05-16	2013-11-21	Rigel Pharmaceuticals, Inc.	Method of treating muscular degradation
DK2863950T3 (en)	2012-06-22	2018-09-03	Galapagos Nv	AMINOTRIAZOLOPYRIDINE USED IN THE TREATMENT OF INFLAMMATION AND PHARMACEUTICAL COMPOSITIONS THEREOF

2009
- 2009-07-12 JO JOP/2009/0259A patent/JO3041B1/ar active
- 2009-07-22 AR ARP090102793A patent/AR072875A1/es active IP Right Grant
- 2009-07-23 TW TW098124908A patent/TWI447118B/zh not_active IP Right Cessation
- 2009-07-23 CL CL2009001637A patent/CL2009001637A1/es unknown
- 2009-07-24 BR BRPI0916659A patent/BRPI0916659B8/pt active IP Right Grant
- 2009-07-24 CN CN200980129088.4A patent/CN102105471B/zh active Active
- 2009-07-24 EP EP09781072.5A patent/EP2361251B1/en active Active
- 2009-07-24 EA EA201170257A patent/EA018587B1/ru not_active IP Right Cessation
- 2009-07-24 ES ES09781073T patent/ES2406691T3/es active Active
- 2009-07-24 JP JP2011519189A patent/JP5480261B2/ja active Active
- 2009-07-24 AU AU2009273144A patent/AU2009273144B2/en not_active Ceased
- 2009-07-24 MX MX2011000758A patent/MX2011000758A/es active IP Right Grant
- 2009-07-24 HR HRP20140681AT patent/HRP20140681T1/hr unknown
- 2009-07-24 CN CN2009801291247A patent/CN102105472B/zh active Active
- 2009-07-24 EP EP09781073A patent/EP2346864B1/en active Active
- 2009-07-24 PL PL09781072T patent/PL2361251T3/pl unknown
- 2009-07-24 US US13/055,936 patent/US8853240B2/en active Active
- 2009-07-24 AU AU2009273143A patent/AU2009273143B2/en active Active
- 2009-07-24 WO PCT/EP2009/059604 patent/WO2010010190A1/en not_active Ceased
- 2009-07-24 KR KR1020117004383A patent/KR101711911B1/ko active Active
- 2009-07-24 MY MYPI20093101A patent/MY157615A/en unknown
- 2009-07-24 MX MX2011000756A patent/MX2011000756A/es active IP Right Grant
- 2009-07-24 PL PL09781073T patent/PL2346864T3/pl unknown
- 2009-07-24 WO PCT/EP2009/059605 patent/WO2010010191A1/en not_active Ceased
- 2009-07-24 JP JP2011519188A patent/JP5559168B2/ja active Active
- 2009-07-24 ME MEP-2014-72A patent/ME02046B/me unknown
- 2009-07-24 BR BRPI0916862A patent/BRPI0916862B8/pt not_active IP Right Cessation
- 2009-07-24 PE PE2009000989A patent/PE20100152A1/es active IP Right Grant
- 2009-07-24 DK DK09781072.5T patent/DK2361251T3/da active
- 2009-07-24 DK DK09781073.3T patent/DK2346864T3/da active
- 2009-07-24 CA CA2730762A patent/CA2730762C/en active Active
- 2009-07-24 CA CA2730757A patent/CA2730757A1/en not_active Abandoned
- 2009-07-24 NZ NZ590646A patent/NZ590646A/en not_active IP Right Cessation
- 2009-07-24 KR KR1020117004384A patent/KR101676391B1/ko not_active Expired - Fee Related
- 2009-07-24 PT PT97810725T patent/PT2361251E/pt unknown
- 2009-07-24 SI SI200930973T patent/SI2361251T1/sl unknown
- 2009-07-24 US US12/508,950 patent/US8242274B2/en active Active
- 2009-07-24 ES ES09781072.5T patent/ES2485913T3/es active Active
- 2009-07-24 RS RS20130214A patent/RS52823B/sr unknown
- 2009-07-24 EA EA201170255A patent/EA018080B1/ru unknown
- 2009-07-24 SI SI200930582T patent/SI2346864T1/sl unknown
- 2009-07-24 HR HRP20130357AT patent/HRP20130357T1/hr unknown
- 2009-07-24 UY UY0001032006A patent/UY32006A/es active IP Right Grant
- 2009-07-24 PT PT97810733T patent/PT2346864E/pt unknown
- 2009-07-24 RS RS20140345A patent/RS53406B/sr unknown
2010
- 2010-12-26 IL IL210262A patent/IL210262A/en active IP Right Grant
- 2010-12-26 IL IL210261A patent/IL210261A/en active IP Right Grant
2011
- 2011-01-14 ZA ZA2011/00396A patent/ZA201100396B/en unknown
- 2011-01-18 DO DO2011000022A patent/DOP2011000022A/es unknown
- 2011-01-18 ZA ZA2011/00472A patent/ZA201100472B/en unknown
- 2011-02-11 MA MA33602A patent/MA32551B1/fr unknown
- 2011-02-16 CR CR20110092A patent/CR20110092A/es unknown
- 2011-02-24 CO CO11022531A patent/CO6361925A2/es active IP Right Grant
2012
- 2012-08-10 US US13/572,043 patent/US20120309784A1/en not_active Abandoned
2013
- 2013-04-24 CY CY20131100335T patent/CY1113945T1/el unknown
- 2013-05-15 SM SM201300051T patent/SMT201300051B/xx unknown
2014
- 2014-06-17 SM SM201400072T patent/SMT201400072B/xx unknown
- 2014-07-29 CY CY20141100572T patent/CY1115569T1/el unknown
- 2014-10-06 US US14/507,396 patent/US9415037B2/en active Active
2016
- 2016-08-15 US US15/236,578 patent/US10206907B2/en active Active

Also Published As

Publication number	Publication date
IL210262A0 (en)	2011-03-31
AU2009273143B2 (en)	2014-01-23
AU2009273143A1 (en)	2010-01-28
JO3041B1 (ar)	2016-09-05
ZA201100472B (en)	2011-10-26
CO6361925A2 (es)	2012-01-20
EA201170255A1 (ru)	2011-08-30
IL210261A (en)	2017-03-30
CL2009001637A1 (es)	2010-02-19
PL2361251T3 (pl)	2014-10-31
TW201008939A (en)	2010-03-01
RS53406B (sr)	2014-10-31
TWI447118B (zh)	2014-08-01
KR101676391B1 (ko)	2016-11-15
PE20100152A1 (es)	2010-03-24
UY32006A (es)	2010-02-26
PT2346864E (pt)	2013-04-04
JP5480261B2 (ja)	2014-04-23
US20100029709A1 (en)	2010-02-04
AR072875A1 (es)	2010-09-29
CA2730757A1 (en)	2010-01-28
MX2011000756A (es)	2011-03-21
PL2346864T3 (pl)	2013-08-30
BRPI0916659A2 (pt)	2019-03-12
SI2346864T1 (sl)	2013-05-31
EA201170257A1 (ru)	2011-08-30
BRPI0916862B8 (pt)	2021-05-25
HRP20130357T1 (en)	2013-05-31
US20150150856A1 (en)	2015-06-04
KR20110053435A (ko)	2011-05-23
JP5559168B2 (ja)	2014-07-23
US10206907B2 (en)	2019-02-19
CN102105472B (zh)	2013-04-17
ME02046B (me)	2015-05-20
US20120309784A1 (en)	2012-12-06
HK1158635A1 (en)	2012-07-20
IL210261A0 (en)	2011-03-31
CN102105471B (zh)	2014-10-15
DOP2011000022A (es)	2011-03-31
CA2730762C (en)	2017-11-21
RS52823B (sr)	2013-10-31
DK2361251T3 (da)	2014-07-21
BRPI0916659B8 (pt)	2021-05-25
EA018587B1 (ru)	2013-09-30
MY157615A (en)	2016-06-30
HK1158634A1 (en)	2012-07-20
BRPI0916659B1 (pt)	2020-12-08
CY1113945T1 (el)	2016-07-27
EP2346864A1 (en)	2011-07-27
PT2361251E (pt)	2014-07-11
CN102105471A (zh)	2011-06-22
AU2009273144A1 (en)	2010-01-28
HRP20140681T1 (hr)	2014-10-24
ZA201100396B (en)	2011-10-26
MA32551B1 (fr)	2011-08-01
CA2730762A1 (en)	2010-01-28
EA018080B1 (ru)	2013-05-30
US8242274B2 (en)	2012-08-14
US20110190260A1 (en)	2011-08-04
ES2485913T3 (es)	2014-08-14
CY1115569T1 (el)	2017-01-04
NZ590646A (en)	2011-11-25
EP2346864B1 (en)	2013-03-06
ES2406691T3 (es)	2013-06-07
WO2010010190A1 (en)	2010-01-28
EP2361251A1 (en)	2011-08-31
SMT201300051B (it)	2013-07-09
BRPI0916862B1 (pt)	2020-08-11
US8853240B2 (en)	2014-10-07
US20170035738A1 (en)	2017-02-09
EP2361251B1 (en)	2014-04-30
SI2361251T1 (sl)	2014-09-30
SMT201400072B (it)	2014-09-08
US9415037B2 (en)	2016-08-16
KR20110045020A (ko)	2011-05-03
DK2346864T3 (da)	2013-05-13
IL210262A (en)	2014-09-30
CN102105472A (zh)	2011-06-22
AU2009273144B2 (en)	2013-10-31
WO2010010191A1 (en)	2010-01-28
MX2011000758A (es)	2011-02-23
KR101711911B1 (ko)	2017-03-03
CR20110092A (es)	2011-03-16
JP2011529033A (ja)	2011-12-01
JP2011529032A (ja)	2011-12-01

Publication	Publication Date	Title
BRPI0916862A2 (pt)	2016-02-10	compostos úteis para o tratamento de doenças degenerativas e inflamatórias
BRPI1015569A2 (pt)	2016-08-16	compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
BRPI1014759A2 (pt)	2016-04-19	composto útil para o tratamento de doenças degenerativas e inflamatórias
BRPI0816784A2 (pt)	2015-03-24	Fatores neuro-endócrinos para o tratamento de doenças degenerativas
BRPI0716844A2 (pt)	2013-10-22	Inidores de quinase úteis para o tratamento de doenças proliferativas
BRPI0810082A2 (pt)	2014-10-21	3-imidazolil-indóis para o tratamento de doenças proliferativas
BRPI0921321A2 (pt)	2018-10-16	métodos para o tratamento de indwcções e tumores
BRPI0813725A2 (pt)	2014-12-30	Métodos e composições para tratamento de doenças
BRPI0908026A2 (pt)	2015-07-21	Métodos para o tratamento de doenças do intestino
PT2367561E (pt)	2015-10-23	Composições e métodos para o tratamento da doença celíaca
PL3354276T3 (pl)	2020-09-21	Kompozycje do leczenia zapalenia przewodu pokarmowego
BR112013014943A2 (pt)	2016-09-13	compostos úteis para o tratamento de aids
BR112012004836A2 (pt)	2019-09-24	pirazinilpiridinas úteis para o tratamento de doenças proliferativas
BRPI0912687A2 (pt)	2016-01-26	uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia
BRPI0912412A2 (pt)	2016-07-26	compostos de pirazina fundidos úteis para o tratamento de doenças degenerativas e inflamatórias.
BRPI0914139A2 (pt)	2015-10-20	composições pediátricas para o tratamento de esclerose múltipla
BRPI0920728A2 (pt)	2015-08-18	Composição estabilizada para tratamento de psoríase
BRPI0915927A2 (pt)	2016-06-07	uso de inibiodores de hdac para o tratamento da doença de hodgkin
BRPI0912679A2 (pt)	2016-01-26	composição farmacêutica para o tratamento de fibromialgia
BR112012002267A2 (pt)	2016-11-08	compostos para o tratamento de inflamação.
BRPI0812105A2 (pt)	2014-11-25	Neramexano para o tratamento de nistagmo
BRPI0822292A2 (pt)	2015-06-30	Fármaco-alvo eficaz para o tratamento de tuberculose
DK2224934T3 (da)	2012-11-05	Anvendelse af osteoblaster til behandling af inflammatoriske rheumatiske sygdomme
IL202502A (en)	2016-04-21	Cxcl11 for the treatment of inflammatory diseases

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-12-03	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2019-12-17	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2020-04-22	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2020-06-30	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-08-11	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/08/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/07/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2025-06-17	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 16A ANUIDADE.
2025-10-14	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2841 DE 17-06-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.